Clinical Trial Update: Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating novel metabolic imaging modalities as predictors of therapeutic efficacy in glioblastoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma

Snippet

Sponsor: Stanford University | Conditions: Glioma, GBM | Phase 2 | Status: SUSPENDED